QurAlis has announced topline results from its Phase I proof-of-mechanism clinical trial of QRL-101 in patients with amyotrophic lateral sclerosis (ALS).
The data provide the first evidence of target engagement with a selective Kv7.2/7.3 ion channel opener in these patients.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Kv7.2/7.3 channels are voltage-gated potassium channels involved in regulating membrane potential and neuronal excitability.
QRL-101 is a selective activator of Kv7.2/7.3 channels in development for addressing disease progression in ALS associated with neuronal hyperexcitability.
This condition affects both genetic and sporadic ALS cases and is often linked to mis-splicing of the KCNQ2 gene in pre-messenger RNA (mRNA). QurAlis is also studying QRL-101 in developmental and epileptic encephalopathies (DEE).
The therapy’s tolerability, safety, and pharmacokinetic (PK) profile matched earlier studies. No serious adverse events or discontinuations due to adverse events occurred.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataQRL-101-04 was a Phase I single-dose, placebo-controlled trial assessing tolerability and safety in ALS patients.
The trial enrolled 12 ALS patients and assessed three dose levels, randomised 3:1 between QRL-101 and placebo.
Its primary endpoint was exploration of the PK and pharmacodynamic relationship, with the trial not powered for statistically significant efficacy.
QurAlis CEO and co-founder Kasper Roet said: “This is the first time we are seeing target engagement of QRL-101 in ALS patients with a biomarker which predicts survival in ALS.
“This is extremely encouraging as new research published in Nature Neuroscience provides additional evidence that loss of TDP-43 function drives mis-splicing of the KCNQ2 potassium channel, producing a dysfunctional isoform that disrupts neuronal excitability in ALS and frontotemporal dementia, further validating this disease mechanism.”
In June 2023, QurAlis received clinical trial authorisation (CTA) in the EU to initiate a first-in-human, Phase I ANQUR clinical trial of QRL-201 for the treatment of ALS.
